Exercise to Boost Immunity in Advanced Cancer

Summary

The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression

Interventions

• Exercise · OTHER

  Exercise programme is the intervention for this study

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who are undergoing first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.
* Age over 18 years old
* Histological or cytological diagnosis of mesothelioma or pancreatic cancer.
* ECOG Performance status 0-1 (to be assessed by clinician)
* Ability to provide informed consent

Exclusion Criteria:

* Prior treatment with systemic anti-cancer treatment
* More than one primary cancer
* Uncontrolled brain or bone metastases
* Patients who have progressed on first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma.
* Patients who have progressed on first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.
* Patients with active co-morbidities that would prevent or limit their participation in the exercise intervention
* Age below 18 years old
* No histological or cytological diagnosis of mesothelioma or pancreatic cancer.
* ECOG Performance status of 2 or more
* Unable to provide informed consent

Sites (2)

• Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom
• Sheffield Hallam University, Sheffield, South Yorkshire, United Kingdom